Company
Acrotech Biopharma
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
7
5 still marketed
Novel approvals
3
Approvals since 2021
1
Originals and new uses
Phase 3 trials
3
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Adquey approved NovelFeb 12, 2026
- Khapzory approved OrphanOct 19, 2018
- Evomela approved Mar 10, 2016
- Evomela approved OrphanMar 10, 2016
- Beleodaq approved NovelAccelerated approvalPriority reviewOrphanJul 3, 2014
- Marqibo Kit approved Accelerated approvalOrphanAug 9, 2012
- Fusilev new use Apr 29, 2011
- Folotyn approved NovelAccelerated approvalPriority reviewOrphanSep 24, 2009
- Fusilev approved OrphanMar 7, 2008
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.